SITE004-0288

SITE004 (DEU) › SITE004-0288

SITE004-0288

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-08-14

enrolled

AEs

0

Serious

0

Dropout signal

–

Adverse events

0

No adverse events recorded. New events are triaged from the Safety tab.

Data queries

0

No data queries. Open queries would appear here for this patient.